Source: Thrombosis Research. Unidade: FMRP
Subjects: RESPIRAÇÃO ARTIFICIAL, ANTICOAGULANTES, TRANSTORNOS DA COAGULAÇÃO SANGUÍNEA, COVID-19
ABNT
LEMOS, Anna Cristina Bertoldi et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thrombosis Research, v. 196, p. 359-366, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.thromres.2020.09.026. Acesso em: 06 nov. 2024.APA
Lemos, A. C. B., Espírito Santo, D. A. do, Salvetti, M. C., Gilio, R. N., Agra, L. B., Pazin Filho, A., & Miranda, C. H. (2020). Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thrombosis Research, 196, 359-366. doi:10.1016/j.thromres.2020.09.026NLM
Lemos ACB, Espírito Santo DA do, Salvetti MC, Gilio RN, Agra LB, Pazin Filho A, Miranda CH. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID) [Internet]. Thrombosis Research. 2020 ; 196 359-366.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.thromres.2020.09.026Vancouver
Lemos ACB, Espírito Santo DA do, Salvetti MC, Gilio RN, Agra LB, Pazin Filho A, Miranda CH. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID) [Internet]. Thrombosis Research. 2020 ; 196 359-366.[citado 2024 nov. 06 ] Available from: https://doi.org/10.1016/j.thromres.2020.09.026